微型植入式脉冲发生器治疗周围神经病理性疼痛的随机对照试验12个月结果
COMFORT试验是首个大型上市后多中心随机对照试验,评估FDA批准的微型植入式脉冲发生器(IPG)经周围神经刺激治疗慢性疼痛。12个月时,治疗应答率为87%,疼痛评分较基线平均降低69%(7.5±1.2降至2.3±1.7;p<0.001),所有患者报告结局均达统计学显著,无严重器械不良事件或口袋痛报告。
要点
- 12个月应答率87%,疼痛平均降低69%,疗效持续。
- 所有患者报告结局均显著改善,安全性良好。
- 多数受试者使用独特编程选项,认为设备易用舒适。
核心结论
- 微型IPG周围神经刺激治疗12个月时疼痛持续大幅降低,患者报告结局改善,安全性良好。
研究设计与样本
- COMFORT研究为大型、上市后、多中心随机对照试验,受试者随机分入活动组(周围神经刺激+常规医疗管理)或对照组(仅常规医疗管理,3个月后允许交叉)。
主要发现
- 12个月时应答率(疼痛评分较基线降低至少50%)为87%,疼痛评分从7.5±1.2降至2.3±1.7,平均降低69%(p<0.001)。
- 所有患者报告结局均达到统计学显著改善。
- 安全性良好,无严重器械不良事件或口袋痛报告。
- 多数受试者使用独特编程选项,并认为设备易用、佩戴舒适。
关键数值与推荐
- 治疗应答定义为疼痛评分较基线降低至少50%。
- 12个月应答率87%,疼痛平均降低69%(基线7.5±1.2降至2.3±1.7;p<0.001)。
临床怎么用
- 对于慢性周围神经病理性疼痛,微型IPG周围神经刺激可作为一种有效且安全的治疗选择,12个月疗效持久。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is paucity of data from randomized controlled trials supporting the use of peripheral nerve stimulation, a well-established therapy for the treatment of chronic pain. This study was undertaken, in part, to provide randomized controlled trial data in support of patient access to appropriate peripheral nerve stimulation therapy. The COMFORT study is the first large, postmarket, multicenter randomized controlled trials investigating the use of a Food and Drug Administration-cleared micro-implantable pulse generator (IPG) for treating chronic pain via peripheral nerve stimulation therapy. METHODS: Consented, eligible subjects were randomized to either the active arm, which received peripheral nerve stimulation and conventional medical management, or the control arm, which received conventional medical management alone and were allowed to cross over to the active arm, after 3 months. Pain and patient-reported outcomes were captured. Therapy responders were subjects who achieved at least a 50% reduction in pain scores compared with baseline. We are reporting the 12-month results of this 36-month study. RESULTS: At 12 months, the responder rate was 87% with a 69% average reduction in pain compared with baseline (7.5±1.2 to 2.3±1.7; p<0.001). Statistical significance was achieved for all patient-reported outcomes. There was an excellent safety profile with no serious adverse device effects or reports of pocket pain. A majority of subjects used unique programming options and found this device easy to use and comfortable to wear. CONCLUSIONS: These 12-month results are consistent with previously reported 6-month outcomes from this study, showing durability of peripheral nerve stimulation treatment with the micro-IPG system; subjects realized sustained large reduction in pain and improvement in patient-reported outcomes following treatment with this micro-IPG system. TRIAL REGISTRATION NUMBER: NCT05287373.
引用
- Hatheway J, Hersel A, Engle M, et al. Clinical study of a micro-implantable pulse generator for the treatment of peripheral neuropathic pain: 12-month results from the COMFORT-randomized controlled trial. Reg Anesth Pain Med. 2026. PMID: 39572166. doi:10.1136/rapm-2024-106099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。